Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
NextBiotics is a synthetic biology company focused on addressing the global threat of antibiotic resistance by developing engineered bacteriophages. The company utilizes CRISPR-Cas technology to enhance the precision and efficacy of phages, allowing them to target and eliminate specific pathogenic bacteria while leaving beneficial microbes intact. Their platform aims to provide a sustainable alternative to traditional antibiotics for applications in human health, including skin conditions and gastrointestinal disorders. By combining phage therapy with advanced genetic engineering, NextBiotics is building a pipeline of targeted antimicrobial solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on NEXTBIOTICS.